In this edition, germline testing ‘should be considered’ for all patients with lung cancer; phase 3 trial of canakinumab misses endpoint; sexual dysfunction common among women with lung cancer, and more.
Read the full coverage here:
Germline testing ‘should be considered’ for all patients with lung cancer, data suggest
Phase 3 trial of canakinumab for non-small cell lung cancer misses endpoint
Sexual dysfunction common among women with lung cancer
Younger patients with lung cancer more likely to have advanced disease at diagnosis
Sotorasib extends PFS in lung cancer subset
References:
Florez N, et al. Abstract MA14. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Potter A, et al. Abstract OA05. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Sorscher S, et al. Abstract 388570. Presented at: ASCO Plenary Series (virtual); Aug. 16, 2022.
